C-WDDPEtheros Pharmaceuticals
enzyme mimetics, neuroprotection, healthspan
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-WDDP
C-WDDPC-WDDPenzyme mimetics, neuroprotection, healthspan
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Etheros states that neuroprotection and healthspan can be improved by developing small molecule drugs that mimic the endogenous enzymes superoxide dismutase and catalase, which it says prevent oxidative and inflammatory injury, especially in neural tissue. The company presents this mechanism as the basis for its lead compound, which it says is neuroprotective in double-blind, placebo-controlled animal studies and extends median lifespan in wild-type mice by about 15% when dosed from middle age.
SourceEtheros states that neural tissue is especially vulnerable to oxidative and inflammatory injury and that mimicking the endogenous protective enzymes superoxide dismutase and catalase with small-molecule drugs can prevent that injury, provide neuroprotection, and improve healthspan. The company also presents its lead compound as supporting this view based on placebo-controlled animal studies and a reported median lifespan extension in wild-type mice when treatment begins in middle age.
SourceEtheros states that neuroprotection and healthspan can be improved by developing small molecule drugs that mimic the endogenous enzymes superoxide dismutase and catalase, which the company says prevent oxidative and inflammatory injury, especially in neural tissue. It presents its lead compound as evidence for this approach, describing it as neuroprotective in double-blind, placebo-controlled animal studies and as extending median lifespan in wild-type mice by around 15% when given from middle age.
Source